Search Vimseltinib Image A CSF1R kinase inhibitor for tenosynovial giant cell tumor (TGCT) Vimseltinib is an investigational, orally administered, potent and highly selective switch-control kinase inhibitor of CSF1R. Vimseltinib was discovered using our proprietary drug discovery platform and was designed to selectively bind to the CSF1R switch pocket. Vimseltinib has demonstrated encouraging preliminary efficacy and safety data in patients with TGCT and is currently being evaluated in a Phase 1/2 clinical study. Unmet Medical Need in TGCT Vimseltinib in TGCT Vimseltinib Phase 3 MOTION Study Related Presentations and Publications twitter linkedin CONTACT US Main navigation Discovery Platform Pipeline Ripretinib Vimseltinib DCC-3116 Preclinical Pipeline Expanded Access Our Medicine QINLOCK® (ripretinib) Who We Are Management Board of Directors Join Us Open Positions Footer Utility Contact Us Terms of Use Privacy Policy Recruiting Privacy Policy Web Accessibility Statement © 2021 Deciphera Pharmaceuticals, Inc. QINLOCK and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC. Deciphera and the Deciphera logo are trademarks of Deciphera Pharmaceuticals, LLC.